Needham Maintains Buy on Vir Biotechnology, Raises Price Target to $20

Benzinga · 1d ago
Needham analyst Joseph Stringer maintains Vir Biotechnology (NASDAQ:VIR) with a Buy and raises the price target from $18 to $20.